AQST News and Press, Aquestive Therapeutics Inc. From 07/19/21

Are These Penny Stocks Worth It After The Stock Market Crash? With the Dow down by over 900 points, investors were searching for penny stocks that could still have growth potential. But, to understand how to make money with penny stocks today, we have to understand why the market dr...

Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021 If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters WARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) -...

syahrir maulana/iStock via Getty Images In response to the complete response letter ((CRL)) received in September, Aquestive Therapeutics ([[AQST]] +7.0%) has submitted its New Drug Application ((NDA)) to the FDA for Libervant (diazepam) Buccal Film for the management of seizure clusters...

Anticipates FDA PDUFA goal date in late 2021 If approved by the FDA for US market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters WARREN, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:...

Aquestive Therapeutics is moving closer to resubmitting Libervant’s NDA. The company expects to submit the NDA by the end of this month, which could put the PDUFA date in 2021. Aquestive continues to fight through COVID-19 headwinds and was able to report impressive Q1 numbers ...

BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years Commercial launch update call is sch...

Aquestive Therapeutics ([[AQST]] -0.7%) appointed seasoned financial executive A. Ernest (Ernie) Toth, Jr., as VP and CFO, effective immediately; currently, he is serving as interim CFO.Press Release For further details see: Aquestive Therapeutics names interim CFO as CFO

WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that A. Ernest (E...

WARREN, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the managemen...